Currently, both drugs have been approved by the Food and Drug Administration (FDA) for the treatment of patients more than 12 years of age with: i) advanced or metastatic RET-mutant MTC; ii) RET fusion-positive metastatic NSCLC, and iii) advanced or metastatic RET fusion-positive thyroid cancer patients who require systemic therapy and who are radioactive iodine refractory. Here, RET is linked to medullary thyroid gland carcinoma.